Onderneming Spark Therapeutics, Inc.
Aandelen
US84652J1034
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ron Philip
CEO | Chief Executive Officer | - | 01-05-17 |
Gallia Levy
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 50 | 25-09-17 | |
Blake Sprayberry
PRN | Corporate Officer/Principal | - | - |
Chris Stevens
PRN | Corporate Officer/Principal | - | 01-01-22 |
Corporate Officer/Principal | - | 01-01-17 | |
Corporate Officer/Principal | - | 16-11-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sean Johnston
BRD | Director/Board Member | - | 17-12-19 |
Bruce Resnick
BRD | Director/Board Member | - | 17-12-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 38 944 971 | 36 835 813 ( 94,58 %) | 421 677 ( 1,083 %) | 94,58 % |
Bedrijfsgegevens
Spark Therapeutics, Inc.
3737 Market Street Suite 1300
19104, Philadelphia
+215 220 9300
http://www.sparktx.com![Adres Spark Therapeutics, Inc.](https://cdn.zonebourse.com/static/address/20798561.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,34% | 122 mld. | |
+19,29% | 113 mld. | |
+18,95% | 26,49 mld. | |
-23,40% | 19,4 mld. | |
-19,03% | 16,24 mld. | |
-20,01% | 15,4 mld. | |
-46,14% | 15,15 mld. | |
+64,09% | 14,93 mld. | |
+4,75% | 13,52 mld. |